The reiteration of a Buy rating and maintenance of a $20 price target by a reputable analyst firm like HC Wainwright & Co. could instill confidence among investors and potentially lead to a positive short-term impact on Poseida Therapeutics' stock price. Analyst ratings, especially with a high price target, often influence investor perception and can lead to increased buying activity.